Col di Lamo 2022 Rosso di Montalcino (14%) Both rich and tangy — with a powerful Sangiovese perfume and sufficient tannin to ...

A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers ...

The SFIO began investigating Vivo, Oppo and Xiaomi in March, examining suspected irregularities exceeding ₹6,000 crore and pointing to significant compliance lapses ...

Domaine René Bouvier, Le Finage 2022 Marsannay 13% 50-year-old vines have yielded another northern Côte d’Or relative bargain ...

Beam Therapeutics Inc. is a Strong Buy with promising trial results, a solid cash runway, and key data updates ahead. Click ...

Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meetingReal-world data reinforces the value of durable, one-time gene ...

SIM as a technology has been around for a decade now. However, global eSIM adoption was around 3% last year and will only ...

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

The cost of forest restoration is a considerable obstacle, sparking discussions in recent years about how to make it ...

The Global Nanomedicine Market is expected to witness a growth rate of 10-12% in the next five years. Ongoing research and ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...